Vivo Capital’s Portfolio Company Aadi BioSceince announced a FDA approval of FYARRO for Patients with Locally Advanced Unresectable or Metastatic Malignant Perivascular Epithelioid Cell Tumor (PEComa)

11月 23rd, 2021|

Neurogastrx Secures $60 Million in Series B Financing and Expands Management Team to Advance Its Pipeline of Transformative Investigational Therapies for Gastrointestinal Disorders

8月 26th, 2021|

Vivo Capital’s venture portfolio company AADI announces a merger agreement with Aerpio Pharmaceuticals with a concurrent $155M in PIPE financing by Aerpio Pharmaceuticals

5月 17th, 2021|

Congratulations to Prof. Frances Arnold, the first American woman to win the Nobel Prize in Chemistry and co-founder of Vivo portfolio company Provivi, for her recent appoint as Co-Chair of President-elect Biden’s Council of Advisors on Science and Technology (PCAST)!

1月 15th, 2021|

Vivo Portfolio Company, Aadi Bioscience and EOC Pharma Announce License and Collaboration Agreement for ABI-009 (FYARROTM) in Greater China

1月 11th, 2021|

VISEN Pharmaceuticals Closes $150 Million Series B Financing to Accelerate the Development and Commercialization of its Innovative Endocrinology Therapies in Greater China

1月 9th, 2021|

Biohaven公司发布了Rimegepant Zydis®口腔溶解片(ODT)III期临床试验积极结果:急性偏头痛的精准疗法,效果迅速、持久

12月 3rd, 2018|

Ascendis Pharma Announces Formation of VISEN Pharmaceuticals to Develop and Commercialize TransCon™ Endocrinology Rare Disease Therapies in China

11月 8th, 2018|

Terns Pharmaceuticals与上海拓臻生物科技有限公司 完成8000万美元B轮融资,用于推进NASH和癌症药物的研发

10月 30th, 2018|

Harmony Biosciences Receives Breakthrough Therapy And Fast Track Designations For Pitolisant Expanded Access Program For Pitolisant Is Open And Patients Are Being Enrolled

5月 21st, 2018|